South Carolina adopts positive coverage of Aerocrine’s FeNO testing in Medicaid program

South Carolina adopts positive coverage of Aerocrine’s FeNO testing in Medicaid
program

SOLNA, Sweden - 9 February, 2012 - Aerocrine AB (OMX Nordic Exchange: AERO)
today announced that South Carolina’s Medicaid program now provides
reimbursement of FeNO testing, bringing the total to 31 states including the
District of Columbia

The State ofSouth Carolinahas added fractional exhaled nitric oxide (FeNO)
testing to the Medicaid fee schedule; this policy change will have a positive
impact on thousands of individuals in the South Carolina Medicaid Program.

Physicians use FeNO to assess eosinophilic airway inflammation, the primary
underlying abnormality that affects the airways of individuals who have asthma.
NIOX MINO is the only product of its kind currently on the market for assessing
FeNO. This innovative technology helps eliminate the uncertainties in asthma
management which contribute to asthma morbidity and mortality. FeNO testing can
help physicians avoid an incorrect diagnosis, indentify patients who will be
responsive to treatment with anti-inflammatory medications such as inhaled
corticosteroids, and alert them to patients who are not adhering to their
treatments..  

“Measurement of exhaled nitric oxide will enable us to provide optimal asthma
management to our patients, said Sonia Bains, MD of the Medical University of
South Carolina. In less than two minutes, this simple and inexpensive test makes
it possible for physicians to better help patients living with asthma with
appropriate therapy and disease control based on the patients’ individual needs.
This is a tremendous victory for patients and physicians who rely on FeNO
testing to accurately provide the best treatment possible on an individual
basis. We are elated that South Carolina Medicaid has validated the need for
this important test and that thousands of patients will receive the care they
need because of this new policy.”

“This simple 2 minute test can help save millions of dollars in unwarranted
medication costs. Asthma has no cure, its all about control. Aerocrine’s
technology can provide the physician with information regarding the patient’s
airway inflammation status which is central to targeting the right treatment
needed to achieve asthma control,” said DrKathy Rickardof Aerocrine. “FeNO
testing is a significant advancement in managing the patient with asthma. Since
the publication of the American Thoracic Guideline on FeNO, this test should be
standard of care in every clinic managing asthma patients.”

Asthma is a chronic inflammatory disease of the airways characterized by
symptoms including wheezing and difficulty in breathing. The disease affects
more than 300 million people around the world, of whom a significant number are
children. Aerocrine’s founders made the original discovery that the levels of
nitric oxide in exhaled breath, FeNO, is elevated in patients with asthma. This
has enabled a quick, effective and proactive method to measure the underlying
inflammation in asthma, rather than being limited to reactively monitor its
negative consequences in the form of symptoms and reduced lung function. The
method has significant value in connection with diagnosis and choice of
appropriate medication, as well as for the continuous management of asthma which
is aimed at controlling the airway inflammation. Today, more than four million
patient tests have been performed around the world using Aerocrine’s NIOX
products.

For more information, contact:

Scott Myers, President & CEO, Aerocrine, Phone: +46 768 788 379

Kathy Hodgdon, director of sales & marketing, Aerocrine Inc., telephone +1 (314)
566 8546

Chip Neff, president, Aerocrine Inc., telephone +1 (919) 696 4267